Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

NEW YORK, July 22, 2015 /PRNewswire/ -- "Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challengess" provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:

- By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
- By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:
- Company financials, sales & revenue figures
- China GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
- Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Top Five Contract Pharmaceutical Export Markets of China
- Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)
- Multinational penetration into the Chinese Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Chinese pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of China, historic and projection analysis
- Chinese economic outlook in comparison to advanced economies
- Three Tier 'Pharmerging' Markets with Potential for Significant Growth
- Prescription drug sales distribution channels in China
- Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche


Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

- An in-depth understanding of the Chinese biopharmaceutical market and it's environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
- Knowledge of how the Chinese pharma market will integrate into the global healthcare market
- Information on key regulatory and government policies
- Data on levels of private and publically funded biopharma studies in China
- Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity


Read the full report: http://www.reportlinker.com/p03086651-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker